Schrodinger (Schrodinger) Cash, Cash Equivalents, Marketable Securities : $463.0 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Schrodinger Cash, Cash Equivalents, Marketable Securities?

Schrodinger's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($548.67 Mil) to Sep. 2023 ($496.28 Mil) but then stayed the same from Sep. 2023 ($496.28 Mil) to Dec. 2023 ($463.00 Mil).

Schrodinger's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($576.48 Mil) to Dec. 2022 ($451.09 Mil) but then increased from Dec. 2022 ($451.09 Mil) to Dec. 2023 ($463.00 Mil).

Schrodinger Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Schrodinger's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schrodinger Cash, Cash Equivalents, Marketable Securities Chart

Schrodinger Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

85.83

642.69

576.48

451.09

463.00

Schrodinger Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															451.09	527.69	548.67	496.28	463.00

Schrodinger Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Schrodinger (NAS:SDGR) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Schrodinger Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Schrodinger's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Schrodinger (Schrodinger) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Schrodinger Inc (NAS:SDGR) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

43Z:Germany

Address

1540 Broadway, 24th Floor, New York, NY, USA, 10036

Website

https://www.schrodinger.com

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Executives

Kenneth Patrick Lorton	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Margaret Dugan	officer: Chief Medical Officer	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Yvonne Tran	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Nancy Thornberry	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Ramy Farid	director, 10 percent owner, officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Geoffrey Craig Porges	officer: EVP & CFO	1540 BROADWAY, 24TH FL., NEW YORK NY 10036
Arun Oberoi	director	100 EAST DAVIE STREET, RALEIGH NC 27601
Robert Lorne Abel	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Karen Akinsanya	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Joel Lebowitz	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David E Shaw	10 percent owner	120 WEST FORTY-FIFTH STREET, 39TH FLOOR, NEW YORK NY 10036
Jorg Weiser	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Jennifer Daniel	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
D'cruz Cony	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Richard Friesner	director, 10 percent owner	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036